ACRS 8-K 2026-11-05

Aclaris Therapeutics, Inc. (ACRS) 8-K dated 2026-11-05 — accession 0001104659-26-123039.

Aclaris Therapeutics, Inc. (ACRS) is a biotechnology company listed on NASDAQ.

ACRS revenue $1.5M

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported ACRS revenue for 2025-12-31 was $7.8M. Net income was -$64.9M. Revenue was down 58.2% from 2024-12-31 to 2025-12-31. ACRS currently screens at market cap $615.9M.

Not investment advice. The ACRS SEC hub lists recent forms. The stock page is the research view.